Hypertension
Conditions
Keywords
essential arterial hypertension, calcium antagonist
Brief summary
This study is aimed to evaluate response rate of the antihypertensive treatment with a calcium antagonist in real life practice, to evaluate patients' quality of life and to collect the following Serbia-specific epidemiology data on hypertension: demographic data, patents characteristics, and patients' management/treatment.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Subject population with essential arterial hypertension currently receiving treatment with a calcium antagonist
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate proportion of patients on antihypertensive pharmacological treatment reaching SBP goals according to the ESC 2007 guidelines (<140 mmHg*). | 24 weeks |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate proportion of patients on antihypertensive pharmacological treatment reaching DBP goals according to the ESC 2007 guidelines (<90 mmHg*). | 24 weeks |
| To collect local epidemiological date on patients with hypertension (demographic data; hypertension management data: treatment, treatment changes and tolerability data). | 24 weeks |
| To evaluate patients quality of life after 12 and 24 weeks by using patients quality of life questionnaire | 24 weeks |
Countries
Serbia